Non - contraceptive benefits and risks of contraception

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 2, 2009, Pages 249-262

  Haider, Zara ^a   D'Souza, Rachel ^a  

^a Margaret Pyke Centre   (United Kingdom)

Author keywords

benefits; contraception; risks; UK medical eligibility criteria (UKMEC)

Indexed keywords

ANTIBIOTIC AGENT; CYPROTERONE ACETATE; DESOGESTREL; DIANE; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORGESTIMATE; NUVURING; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; STEROID; UNCLASSIFIED DRUG;

ACNE VULGARIS; ALLERGY; AMENORRHEA; ARTICLE; BLEEDING DISORDER; BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHLOASMA; CLINICAL TRIAL; COLORECTAL CANCER; CONTRACEPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; EPILEPSY; EVIDENCE BASED PRACTICE; HUMAN; INFECTION CONTROL; INTRAUTERINE CONTRACEPTIVE DEVICE; IRON DEFICIENCY ANEMIA; LIPID METABOLISM; LOW DRUG DOSE; MENORRHAGIA; MENSTRUATION DISORDER; OVARY CANCER; OVARY CYST; OVARY TUMOR; PELVIC INFLAMMATORY DISEASE; PIGMENT DISORDER; POSTMARKETING SURVEILLANCE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SICKLE CELL CRISIS; SIDE EFFECT; THROMBOPHILIA; TREATMENT DURATION; UTERINE CERVIX CARCINOMA; UTERUS MYOMA; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; ATTITUDE TO HEALTH; CONTRACEPTIVE BEHAVIOR; EVIDENCE BASED MEDICINE; FEMALE; GENITAL DISEASES, FEMALE; MENSTRUATION DISTURBANCES; PRACTICE GUIDELINE; PREGNANCY; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; SEXUALLY TRANSMITTED DISEASES;

CONTRACEPTION; CONTRACEPTION BEHAVIOR; EVIDENCE-BASED MEDICINE; FEMALE; GENITAL DISEASES, FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MENSTRUATION DISTURBANCES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES;

EID: 60549101659     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2008.12.003     Document Type: Article

References (96)

1. The UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2005/2006) (July 2006), Faculty of Family Planning and Reproductive Healthcare, London. Available from: www.fsrh.org.uk
2. Pattman R, Snow M, Handy P et al. (eds.) Oxford handbook of genitourinary medicine, HIV and AIDS. Oxford University Press, 2005.
3. About latex allergy from website. Available from:. www.hse.gov.uk/latex/about.htm
4. Wilkinson D., Ramjee G., Tholandi M., et al. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database Syst Rev 4 (2002) CD 003936
5. Phillips D.M., Sudol K.M., Taylor C.L., et al. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 70 (2004) 107-110
6. Fraser I., and McCarron G. Randomised trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 31 (1991) 66-70
7. Lethaby A., Augood C., and Duckitt K. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev (2000)
8. Vessey M., Painter R., and Mant J. Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: findings in a large cohort study. Br J Fam Plann 22 (1996) 166-169
9. Heavy menstrual bleeding. National Collaborating Centre for Women's and Children's Health. Commissioned by the National Institute for Health and Clinical Excellence (2007), RCOG Press
10. Hendrix S.L., and Alexander N.J. Primary dysmenorrhoea treatment with a Desogestrel-containing low-dose oral contraceptive. Contraception 66 (2002) 393-399
11. Combined oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 4 (2001)
12. Milman N., Kirchhoff M., and Jorgensen T. Iron status markers, serum ferritin and haemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity and postmenopausal hormone treatment. Ann Hematol 65 2 (1992 Aug) 96-102
13. Lanes S.F., Birmann B., Walker A.M., et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 166 (1992) 956-961
14. Holt V.L., Daling J.R., McKnight B., et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contaceptives. Obstet Gynecol 79 (1992) 529-533
15. Westhoff C., Britton J.A., Gammon M.D., et al. Oral contraceptive and benign ovarian tumors. Am J Epidemiol 152 (2000) 242-246
16. Arowojolu A.O., Gallo M.R., Grimes D.A., et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 3 (2004) CD004425
17. Rosen M.P., Breitkopf D.M., and Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 188 5 (2003 May) 1158-1160
18. Redmond G.P., Olson W.H., Lippman J.S., et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89 4 (1997 Apr) 615-622
19. Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77 4 (2008) 249-256
20. Committee on Safety of Medicines (CSM). Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). MCA/CSM Current Problems in Pharmacovigilance 28 (2002) 9-10
21. Monographs on the evaluation of carcinogenic risks to humans combined estrogen-progestogen contraceptives vol. 91 (2005), International Agency for Research on Cancer (IARC)
22. Vessey M., Painter R., and Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 362 (2003) 185-191
23. Whittemore A.S., Balise R.R., Pharouh P.D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 (2004) 1911-1915
24. International Agency for Research in Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and post menopausal hormonal therapy vol. 72 (1999), WHO IARC, Lyons
25. Weiderpass E., Adami H.O., Baron J.A., et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10 (1999) 277-284
26. Fernandez E., Vecchia C.L., Balducci A., et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 84 (2001) 722-727
27. Hannaford P., and Elliot A. Use of exogenous hormones by women and colorectal cancer: evidence for the Royal College of General Practitioners' Oral Contraceptive Study. Contraception 71 (2005) 95-98
28. Ross R.K., Pike M.C., and Vessey M.P. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J 293 (1986) 359-362
29. Wise L.A., Palmer J.R., Harlow B.L., et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 159 (2004) 113-123
30. Vercillini P., Trespidi L., Colombo A., et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 60 (1993) 75-79
31. Parazzini F., Di Cinto E., Chatenoud L., et al. Estroprogestin vs. gonadotropin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomised trial. Eur J Obstet Gynecol Reprod Biol 88 (2000) 11-14
32. The investigation and management of endometriosis. Green top guideline no. 24 (2006), RCOG. Available from: www.rcog.org.uk/resources/Public/pdf/endometriosis
33. Rivera-Tovar A.D., and Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 147 (1990) 1634-1636
34. Bancroft J., and Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 37 (1993) 195-202
35. Mansour D. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 7 Suppl. 3 (2002) 35-41
36. Lopez L.M., Kaptein A., and Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 1 (2008 Jan 23) CD006586
37. Burkman R.T., Collins J.A., Schulman L.P., et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185 (2001) S4-S12
38. Kuohung W., Borga T.T.A., and Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based approach. Contraception 61 (2000) 77-78
39. Petitti D.B., Piaggio G., Mehta S., et al. WHO study of hormonal contraception and bone health. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 95 (2000) 736-744
40. Reed S.D., Scholes D., LaCroix A.Z., et al. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 68 (2003) 177-182
41. Castelo-Branco C., Vicente J.J., Pons F., et al. Bone mineral density in young, hypothalamic oligomenorrheic women treated with oral contraceptives. J Reprod Med 46 (2001) 875-879
42. Munoz M.T., Morande G., Garcia-Centerera J.A., et al. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 146 (2002) 45-50
43. Spector T.D., and Hochberg M.C. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 43 (1990) 1221-1230
44. Drossaers-Bakker K.W., Zwinderman A.H., van Zeben D., et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long-term rheumatoid arthritis. Ann Rheum Dis 61 (2002) 405-408
45. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Medicines Commission. MCA/CSM Current Problems in Pharmacovigilence 25 (1999) 12
46. Dinger J.C., Heinemann L.A., and Kuhl-Habich K. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
47. Vasilakis-Scaramozza C., and Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429
48. MHRA. Combined hormonal contraceptives: venous thromboembolism - update. Drug Safety Update 1 9 (April 2008)
49. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen containing oral contraceptives on venous thromboembolism. Lancet 346 (1995) 1575-1582
50. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65 (2002) 187-196
51. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
52. British society for haematology. Investigation and management of heritable thrombophilia. Br J Haematol 114 (2001) 512-528
53. Becker W.J. Migraine and oral contraceptives. Can J Neurol Sci 24 (1997) 16-21
54. Baillargeon J.P., McClish D.K., Essah P.A., et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 (2005) 3863-3870
55. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 348 (1996) 498-505
56. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 348 (1996) 505-510
57. Croft P., and Hannaford P. Risk factors for acute myocardial infarction in women - evidence from RCGP Oral Contraceptive Study. BMJ 298 (1989) 165-168
58. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
59. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (2002) 2025-2032
60. Silvera S.A.N., Miller A.B., and Rohan T.E. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 16 (2005) 1059-1063
61. Moreno V., Bosch F.X., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 (2002) 1085-1092
62. Hannaford P., Selvaraja S., Elliot A., et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraceptive study. Br Med J 335 (2007) 651
63. Neuberger J., Forman D., Doll R., et al. Oral contraceptives and hepatocellular carcinoma. Br Med J 292 (1986) 1355-1357
64. The Royal College of General Practitioners. An interim report from the Oral Contraception Study of the Royal College of General Practitioners. Oral Contraception and Health (1974), Pitman Medical, London
65. Sangi-Haghpeykar H., Poindexter A.N., Bateman L., et al. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 88 (1996) 227-233
66. Andersson J.K., and Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97 (1990) 690-694
67. Hidalgo M., Bahamondes L., Perotti M., et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 65 (2002) 129-132
68. Irvine G.A., Campbell-Brown M.B., Lumsden M.A., et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 105 (1998) 592-598
69. Milsom I., Andersson K., Andersch B., et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 164 (1991) 879-883
70. Lahteenmaki P., Haukkamaa M., Puolakka J., et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J 316 (1998) 1122-1126
71. Lethaby A.E., Cooke I., and Rees M. Progesterone or progesterone-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 4 (2005) CD002126
72. Raudaskoski T., Tapanainen J., Tomas E., et al. Intrauterine 10 mg and 20 mg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 109 (2002) 136-144
73. Hampton N.R., Rees M.C., Lowe D.G., et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 20 (2005) 2653-2660
74. Wildemeersch D., Janssens D., Pylyser K., et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 57 (2007) 210-213
75. Varma R., Soneja H., Bhatia K., et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia- a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 139 (2008) 169-175
76. Chan S.S., Tam W.H., Yeo W., et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. Br J Obstet Gynaecol 114 (2007) 1510-1515
77. Barrington J.W., and Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 104 (1997) 614-616
78. Fedele L., Bianchi S., Zanconato G., et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 75 (2001) 485-488
79. Vercellini P., Frontino G., De Giorgi O., et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 80 (2003) 305-309
80. De Ceulaer K., Gruber C., Hayes R., et al. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 2 (1982) 229-231
81. Mattson R.H., Cramer J.A., Caldwell B.V., et al. Treatment of seizures with medroxyprogesterone acetate: a preliminary report. Neurology 34 (1984 Sep) 1255-1258
82. Bitzer J., Tschudin S., Alder J., et al., Swiss Implanon Study Group. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Study Group. Eur J Contracept Reprod Health Care 9 (2004) 278-284
83. Desogestrel-only pill (Cerazette). New product review (April 2003), Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
84. Inki P., Hurskainen R., Palo P., et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 20 (2002) 381-385
85. Beerthuizen R., van Beek A., Massai R., et al. Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15 (2000) 118-122
86. Clark M.K., Sowers M.R., Nichols S., et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 82 (2004) 1580-1586
87. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2008) 67-76
88. Scholes D., LaCroix A.Z., Ott S.M., et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 93 (1999) 233-238
89. Scholes D., La Croix A.Z., Ichikawa L.E., et al. Change in bone mineral density among adolescent woman using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
90. Committee on Safety of Medicines. Updated prescribing advice on the effect of Depo-Provera Contraception on bone (2006), Published by the MHRA
91. Bonny A.E., Ziegler J., Harvey R., et al. Weight gain in obese and non-obese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills or no hormonal contraceptive method. Arch Pediatr Adolesc Med 160 (2006) 40-45
92. Kongsayreepong R., Chutivongse S., George P., et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 47 (1993) 177-191
93. World Health Organisation (WHO). Selected practice recommendations for contraceptive use (2002), WHO, Geneva, Switzerland
94. Cox M., Tripp J., and Blackwell S. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 28 (2002) 69-72
95. O'brien P.A., and Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev 1 (2005) CD003282
96. Farley T.N.M., Rosenberg M.J., Rowe P.J., et al. Intrauterine contraceptive devices and pelvic inflammatory disease: an international perspective. Lancet 339 (1992) 785-788